Investigation of HIMS: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

The FTC filed a lawsuit against Hims & Hers (HIMS) on July 29 alleging deceptive and unlawful privacy practices, including sharing sensitive patient health information with Snap and Meta (via Meta’s advertising ecosystem). After the news, HIMS shares dropped more than 14%. The article also frames potential federal securities-law claims for investors who purchased the stock and suffered significant losses.

Analysis

HIMS is the cleanest loser because this is not just a headline legal risk; it goes straight at the economics of consumer health distribution. If regulators force a reset in data-sharing practices, the first derivative is higher CAC and lower ad conversion, but the second-order effect is worse: lower confidence from patients and partners can slow repeat usage and raise churn, which matters more for valuation than any one-time settlement.

META and SNAP are not economically exposed in a material way from the lawsuit itself, but they become part of the compliance narrative whenever health-advertiser data flows are scrutinized. That creates a modest overhang for the broader direct-to-consumer healthcare cohort because platform policies can tighten before courts finish, which can raise acquisition costs across telehealth, pharmacy, and wellness apps. The likely beneficiaries are more traditional healthcare distributors and insurer-linked channels that rely less on paid social to acquire users.

The market reaction can easily overshoot in both directions. Near term, a relief rally is possible if the company frames this as a finite legal issue and still prints stable gross adds, but that would only address the surface-level fine risk, not the operating model risk. The bearish thesis is falsified if the next 1-2 quarters show no deterioration in acquisition efficiency or retention; otherwise this becomes a months-long multiple compression story rather than a one-day event.

Key Decisions for Investors

• Short HIMS on any post-selloff rebound over the next 1-3 weeks; target a 15-25% downside move if CAC rises or management turns defensive, with a tight stop if the stock fully retraces the gap on unchanged growth metrics.
• Buy 3-6 month HIMS put spreads, sized for a legal-duration event rather than an earnings miss; prefer strikes 10-15% below spot to limit theta while keeping exposure to a longer trust reset.
• Pair trade: short HIMS / long UNH or CVS for a 1-3 month relative-value expression on regulated data practices versus direct-to-consumer advertising dependence; thesis breaks if HIMS proves acquisition economics are unchanged.
• Avoid overreacting by shorting META or SNAP outright; use them only as a small basket hedge if you want to express broader concern about health-ad data scrutiny, since direct financial exposure appears limited.
• Set an alert for the next HIMS earnings update on gross adds, churn, and paid-social efficiency; if any of those weaken sequentially, press the short because the multiple will likely compress before absolute revenue shows the damage.